Elucidating The Cellular Processes That Are Critical For P53 Mediated Tumour Suppression
Funder
National Health and Medical Research Council
Funding Amount
$1,016,108.00
Summary
p53 is a tumour suppressor gene that is mutated in ~50% of human cancers. Mutations in p53 cause development of cancer and render malignant cells resistant to chemotherapy. We have identified genes regulated by p53 that appear critical for its tumour suppressive function. In this project, we will use innovative novel genetic tools to discover the cellular and biochemical functions of these genes. The ultimate goal of our studies is to identify novel targets for anti-cancer therapy.
HIC1 Prevents Tumour Initiation By Maintaining Genomic Stability
Funder
National Health and Medical Research Council
Funding Amount
$531,681.00
Summary
Chromosomes are large structures that package the genome. Abnormalities in the structure and function of chromosomes are now recognised an in important driver of cancer. Using a genetically engineered mouse model this project seeks to understand how this process evolves from the very earliest stages in the evolution of a tumour.
Targeting Homeobox Genes In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$658,739.00
Summary
Acute myeloid leukaemia (AML) is a common blood cancer with dire clinical prognosis due to a lack of targeted molecular therapies. In this proposal we will identify new ways of targeting transcription factor proteins that are overexpressed in AML and promote leukaemia by repressing normal cellular growth controls. This may lead to novel methods to target leukaemic stem cells to specifically eliminate myeloid leukemia
Role Of MACROD2 Loss In DNA Repair, Chromosomal Instability And Development Of Colorectal Cancer: Clinical And Therapeutic Implications
Funder
National Health and Medical Research Council
Funding Amount
$772,871.00
Summary
The MACROD2 gene is deleted in one-third of human bowel cancers. We have discovered that MACROD2 deletion causes defective DNA repair and tumour chromosomal instability. Here, we will use novel laboratory models to show that MACROD2 loss actively promotes bowel cancer development. We will test the clinical implication of MACROD2 loss for predicting tumour therapy response and will investigate the potential of exploiting this deficiency for drug targeting.
Role Of PTEN Catalytic Function In Suppression Of Cancer And Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$758,319.00
Summary
PTEN mutations are frequently described in various types of cancer. This proposal outlines different experimental strategies to probe how modulation of distinct PTEN functions can affect signalling pathways and be responsible for oncogenic outcomes. We will use animal models and cell lines in culture to identify new signatures/biomarkers to stratifying patients on genetic and molecular bases, and to facilitate the design of tailored combinational therapies directed toward cancer eradication.
Genomic Analysis Of The Novel Epigenetic Modifier Smchd1 As A Tumour Suppressor
Funder
National Health and Medical Research Council
Funding Amount
$619,142.00
Summary
Epigenetic modifications are changes made to our DNA that act like punctuation marks in the genome, to instruct the cell when to turn genes on and when to switch them off. Epigenetic control is critical to range of different biological processes, and also goes awry in cancer. We are specifically interested in the role of one new protein involved in epigentic control and characterising its role as a tumour suppressor.
Functional Characterization And Therapeutic Targeting Of The Novel Long Noncoding RNA MYCN-AS
Funder
National Health and Medical Research Council
Funding Amount
$646,979.00
Summary
Cancer is the most common cause of death from diseases in children. Neuroblastoma is the most common solid tumour in early childhood. In this application, we will establish the role of gene amplification of a novel long non-protein-coding RNA in blocking tumour suppressor gene expression and promoting neuroblastoma progression. We will also establish the anti-cancer efficacy of a novel therapy targeting the long non-protein-coding RNA.
How Does The Tumour Suppressor: Nerfin-1 Prevent Dietary Dependent Tumour Growth?
Funder
National Health and Medical Research Council
Funding Amount
$630,942.00
Summary
The influence of diet has been linked to tumour growth for decades, however, there is little scientific evidence to support or disprove this. In this study, we will assess the effect of diet on tumours in fruit flies. The metabolic genes which regulate the growth of fly tumours will then be studied in human brain tumours. Our studies will ultimately shed light on how tissue growth is controlled by dietary intake, and have the potential to inform the way that we treat and manage human cancers.
FOXP3 Regulated MicroRNAs: A Novel Component Of FOXP3 Tumour Suppressor Function In Breast Epithelial Cells.
Funder
National Health and Medical Research Council
Funding Amount
$554,716.00
Summary
Until there is a cure, breast cancer research must continue to discover new targets for therapy. We have novel insight into a new tumour supressor; FOXP3, and have identified the genes it regulates in T cells. We can now apply this information to normal breast tissues to reveal the mechanism and targets that FOXP3 controls to prevent cancer
Nuclear Receptors And Triple Negative Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$681,979.00
Summary
This project will explore the potential for a nuclear receptor known as the thyroid receptor to suppress growth of breast cancer using cell culture models and mouse models. We hope to show that activating the thyroid receptors leads to a reduction in breast cancer growth providing evidence that the thyroid receptor pathway could be targeted for therapy.